RIZATRIPTAN BENZOATE

N/A

Manufactured by Organon LLC

24,816 FDA adverse event reports analyzed

Last updated: 2026-04-14

About RIZATRIPTAN BENZOATE

RIZATRIPTAN BENZOATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Organon LLC. The most commonly reported adverse reactions for RIZATRIPTAN BENZOATE include DRUG INEFFECTIVE, NAUSEA, HEADACHE, MIGRAINE, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RIZATRIPTAN BENZOATE.

Top Adverse Reactions

DRUG INEFFECTIVE1,398 reports
NAUSEA1,112 reports
HEADACHE997 reports
MIGRAINE962 reports
OFF LABEL USE796 reports
FATIGUE641 reports
PAIN601 reports
PRODUCT USE IN UNAPPROVED INDICATION499 reports
HYPERHIDROSIS478 reports
VOMITING454 reports
DIARRHOEA433 reports
DIZZINESS418 reports
DYSPNOEA415 reports
ANXIETY389 reports
SEDATION376 reports
NIGHTMARE374 reports
HYPERSENSITIVITY348 reports
NEPHROLITHIASIS348 reports
ARTHRALGIA344 reports
DEPRESSION337 reports
INSOMNIA328 reports
MALAISE316 reports
FEELING ABNORMAL283 reports
DRUG INTOLERANCE277 reports
ABDOMINAL PAIN273 reports
WEIGHT DECREASED273 reports
COUGH272 reports
FALL270 reports
SINUSITIS252 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION248 reports
PAIN IN EXTREMITY237 reports
PARAESTHESIA236 reports
SOMNOLENCE233 reports
ASTHENIA230 reports
DYSPHONIA218 reports
SWELLING FACE214 reports
PYREXIA210 reports
PRURITUS209 reports
BACK PAIN203 reports
CONSTIPATION201 reports
SWOLLEN TONGUE201 reports
RASH199 reports
INJECTION SITE PAIN198 reports
ABDOMINAL PAIN UPPER194 reports
HYPERTENSION191 reports
CHEST PAIN189 reports
CONDITION AGGRAVATED188 reports
ANGIOEDEMA186 reports
HYPOAESTHESIA182 reports
MUSCLE SPASMS182 reports
PRODUCT DOSE OMISSION ISSUE180 reports
PNEUMONIA176 reports
DRUG HYPERSENSITIVITY172 reports
WEIGHT INCREASED168 reports
TREMOR164 reports
MEMORY IMPAIRMENT156 reports
URINARY TRACT INFECTION154 reports
NASOPHARYNGITIS152 reports
ASTHMA146 reports
BRONCHITIS144 reports
CHEST DISCOMFORT142 reports
SUICIDAL IDEATION140 reports
MYALGIA139 reports
DYSPEPSIA137 reports
CONFUSIONAL STATE136 reports
DRUG INTERACTION136 reports
PULMONARY EMBOLISM136 reports
BLOOD PRESSURE INCREASED133 reports
URTICARIA133 reports
GAIT DISTURBANCE132 reports
LOSS OF CONSCIOUSNESS132 reports
ALOPECIA128 reports
PALPITATIONS128 reports
INJURY126 reports
VISION BLURRED125 reports
INFLUENZA122 reports
ABDOMINAL DISCOMFORT118 reports
DEEP VEIN THROMBOSIS117 reports
DECREASED APPETITE113 reports
FLUSHING111 reports
PRODUCT USE ISSUE111 reports
TREATMENT FAILURE110 reports
MULTIPLE SCLEROSIS RELAPSE109 reports
MUSCULAR WEAKNESS109 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS109 reports
COVID 19106 reports
STRESS105 reports
CHILLS103 reports
DEHYDRATION102 reports
DRUG DOSE OMISSION102 reports
GASTROOESOPHAGEAL REFLUX DISEASE102 reports
CEREBROVASCULAR ACCIDENT99 reports
EMOTIONAL DISTRESS98 reports
NECK PAIN98 reports
CHOLELITHIASIS93 reports
NEUROPATHY PERIPHERAL92 reports
NO ADVERSE EVENT92 reports
CONTUSION91 reports
ERYTHEMA88 reports
INCORRECT DOSE ADMINISTERED88 reports

Report Outcomes

Out of 9,810 classified reports for RIZATRIPTAN BENZOATE:

Serious 58.1%Non-Serious 41.9%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female7,819 (85.6%)
Male1,276 (14.0%)
Unknown43 (0.5%)

Reports by Age

Age 53391 reports
Age 41321 reports
Age 50183 reports
Age 55151 reports
Age 44148 reports
Age 42146 reports
Age 57143 reports
Age 43142 reports
Age 46142 reports
Age 52140 reports
Age 48138 reports
Age 49137 reports
Age 40135 reports
Age 54131 reports
Age 51129 reports
Age 56126 reports
Age 47125 reports
Age 38121 reports
Age 59121 reports
Age 39120 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RIZATRIPTAN BENZOATE?

This profile reflects 24,816 FDA FAERS reports that mention RIZATRIPTAN BENZOATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RIZATRIPTAN BENZOATE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, NAUSEA, HEADACHE, MIGRAINE, OFF LABEL USE, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RIZATRIPTAN BENZOATE?

Labeling and FAERS entries often list Organon LLC in connection with RIZATRIPTAN BENZOATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.